O3-8-3Peritoneum metastasis (PM) as a prognostic factor for anti-PD-1/PD-L1 monotherapy in metastatic gastric cancer (MGC)
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Oncology"
DOI: 10.1093/annonc/mdx697.081
Abstract: Results: Patient characteristics were as follows: median age (range), 68 (47-83); ECOG PS 0/1, 21/10; PMþve/-ve, 12/19; No. of prior chemotherapy regimens 1-2/ 3, 11/20; and absolute eosinophil count (AEC)< 150/ 150/ml, 14/17. Objective response… read more here.
Keywords: metastasis prognostic; factor anti; prognostic factor; cohort ... See more keywords
Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort
Sign Up to like & getrecommendations! Published in 2021 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2020-002092
Abstract: Background Although the Society for Immunotherapy of Cancer (SITC) Immunotherapy Resistance Taskforce recently defined primary and secondary resistance to anti-programmed cell death protein 1 (anti-PD-1) therapy, there is lack of real-world data regarding differences in… read more here.
Keywords: advanced melanoma; secondary resistance; resistance; anti monotherapy ... See more keywords
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-21-1283
Abstract: Purpose: Programmed cell death receptor-1 (PD-1) inhibitors are frontline therapy in advanced melanoma. Severe immune-related adverse effects (irAEs) often require immunosuppressive treatment with glucocorticoids (GCCs), but GCC use and its correlation with patient survival outcomes… read more here.
Keywords: gcc use; post irae; anti monotherapy; irae ... See more keywords
Predictable early onset high-dose-glucocorticoid-associated-irAE and its predictive role in anti-PD-1 monotherapy treated advanced melanoma patients.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.9544
Abstract: 9544 Background: Though uncommon, a subgroup of patients with melanoma develop early-onset severe immune-related adverse effects (irAEs) that require immunosuppressive treatment with high-dose glucocorticoids (HD-GCCs). We aimed to examine the impact of early onset HD-GCC-associated-irAE… read more here.
Keywords: early onset; hga irae; anti monotherapy; irae ... See more keywords
Organ site-specific radiological responses in anti-PD-1 monotherapy treated advanced melanoma patients.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.9552
Abstract: 9552 Background: Melanoma is notorious for its high degree of heterogeneity with the implication that metastases in different sites react differently to immunotherapy. We aimed to explore the site-specific response pattern in anti-PD-1 monotherapy treated… read more here.
Keywords: melanoma patients; advanced melanoma; monotherapy; site specific ... See more keywords
Outcomes of retreatment with anti-PD-1 monotherapy after response to first course in patients with cutaneous melanoma.
Sign Up to like & getrecommendations! Published in 2020 at "Future oncology"
DOI: 10.2217/fon-2020-0314
Abstract: Aim: To determine outcomes of retreatment with anti-PD-1 monotherapy for melanoma. Materials & methods: This retrospective study included adults with unresectable cutaneous melanoma who achieved stable disease (SD) or better after anti-PD-1 monotherapy and were… read more here.
Keywords: retreatment anti; anti monotherapy; response; cutaneous melanoma ... See more keywords
Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2021.691032
Abstract: Background Anti-PD-1 monotherapy is the standard therapy for advanced melanoma patients, including those with NRAS mutations. The influence of NRAS mutation on immunotherapy, especially in noncutaneous melanoma, is largely uncharacterized. Materials and Methods We analyzed… read more here.
Keywords: melanoma; advanced melanoma; nras mutation; nras mutations ... See more keywords